76
|
Mattap SM, Aitken D, Wills K, Halliday A, Ding C, Han W, Munugoda I, Graves SE, Lorimer M, Cicuttini F, Jones G, Laslett LL. Patellar tendon enthesis abnormalities and their association with knee pain and structural abnormalities in older adults. Osteoarthritis Cartilage 2019; 27:449-458. [PMID: 30529466 DOI: 10.1016/j.joca.2018.11.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2018] [Revised: 11/07/2018] [Accepted: 11/19/2018] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To describe associations between presence of patellar tendon enthesis (PTE) abnormalities and symptoms, structural abnormalities, and total knee replacement (TKR) in older adult cohort. METHODS PTE abnormalities (presence of abnormal bone signal and/or bone erosion), were measured on T2-weighted magnetic resonance (MR) images at baseline in 961 community-dwelling older adults. Knee pain and function limitation were assessed using Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Bone marrow lesions (BMLs), cartilage volume and defects score, and infrapatellar fat pad (IPFP) area were measured using validated methods. Incidence of TKR was determined by data linkage. RESULTS Participants with abnormal PTE bone signal and/or erosion was 20%. Cross-sectionally, presence of PTE abnormalities was associated with greater pain intensity while going up and down stairs (β = 0.22 (95% confidence interval (CI); 0.03, 0.41)), greater risk of femoral BMLs (RR = 1.46 (1.12, 1.90)) and worse tibial cartilage defects score (RR = 1.70 (1.16, 2.47), and smaller IPFP area (β = -0.27 (-0.47, -0.06) cm2), after adjustment of confounders. Longitudinally, presence of baseline PTE abnormalities was associated with a deleterious increase in tibial BML size (RR = 1.52 (1.12, 2.05)) over 10.7 years but not symptoms, other structural changes, or TKR. CONCLUSION PTE abnormalities are common in older adults. Presence of cross-sectional but not longitudinal associations suggests they are commonly co-exist with other knee structural abnormalities but may not play a major role in symptom development or structural change, excepting tibial BMLs.
Collapse
|
77
|
Jung J, Joo Y, Kim KE, Kim H, Kim Y, Lee E, Lee HB, Moon HG, Han W. Efficacy of combination of indigocarmine dye and radioisotope dye injection for sentinel lymph node biopsy: positive node rate, axillary recurrence rate and disease free survival for over 5 years follow up results. Breast 2019. [DOI: 10.1016/s0960-9776(19)30413-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
78
|
Liu J, Liu YR, Wang YZ, Han W, Chen H, Chen Y, Wang JZ, Mo XD, Zhang YY, Yan CH, Sun YQ, Chen YY, Wang Y, Xu LP, Zhang XH, Liu KY, Huang XJ, Chang YJ. [The comparison of predicting clinical outcomes between immunolophenotype and hematological complete remission before human leukocyte antigen-matched sibling donor transplantation in acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:617-623. [PMID: 30180459 PMCID: PMC7342848 DOI: 10.3760/cma.j.issn.0253-2727.2018.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
目的 比较移植前免疫表型缓解(ICR)和血液形态学缓解对急性髓系白血病(AML)患者同胞HLA相合造血干细胞移植(MSDT)疗效的预测价值。 方法 回顾性分析182例接受MSDT的AML患者(除外急性早幼粒细胞白血病),将移植前血液形态学缓解分为血细胞恢复的完全缓解(CR)、血小板未恢复的CR(CRp)、血小板和中性粒细胞均未恢复的CR(CRi),将多参数流式细胞术检测微小残留病阴性定义为ICR。 结果 ①全部182例AML患者中,男97例,女85例,中位年龄41(4~62)岁。②移植前CR、CRp+CRi率分别为80.8%(147/182)、19.2%(35/182);移植前CRp+CRi组、CR组的预期4年累积复发率(CIR)[(11.0±4.3)%对(16.0±7.1)%,χ2=0.274,P=0.600]、非复发死亡率(NRM)[(14.0±4.3)%对(9.0±6.3)%,χ2=0.913,P=0.339]、无白血病生存(LFS)率[(75.0±5.1)%对(75.0±8.3)%,χ2=0.256,P=0.613]、总生存(OS)率[(77.0±5.2)%对(80.0±8.1)%,χ2=0.140,P=0.708]差异均无统计学意义。③移植前ICR组(147例)与非ICR组(35例)比较,4年CIR较低[(11.3±3.4)%对(55.2±8.8)%,χ2=32.687,P<0.001],LFS率[(76.2±4.7)%对(32.8±8.7)%,χ2=26.234,P<0.001]和OS率[(79.0±4.7)%对(39.0±9.1)%,χ2=25.253,P<0.001]较高,NRM差异无统计学意义[(12.5±4.1)%对(12.0±7.1)%,χ2=1.002,P=0.656]。④多因素分析显示,移植前非ICR是影响AML患者MSDT后复发[HR=11.026(95% CI 4.685~25.949),P<0.001]、LFS[HR=5.785(95% CI 2.974~11.254),P< 0.001]和OS[HR=5.578(95%CI 2.575~27.565),P<0.001]的独立危险因素。 结论 移植前ICR对AML患者MSDT的疗效预测价值优于HCR。
Collapse
|
79
|
Dou XL, Zhao T, Xu LP, Zhang XH, Wang Y, Chen H, Chen YY, Yan CH, Han W, Wang FR, Wang JZ, Chen Y, Jiang H, Zhu HH, Jia JS, Wang J, Jiang B, Wang DB, Liu KY, Huang XJ, Jiang Q. [Age-related clinical characteristics and prognosis in non-senile adults with acute myeloid leukemia]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2019; 39:969-976. [PMID: 30612396 PMCID: PMC7348229 DOI: 10.3760/cma.j.issn.0253-2727.2018.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
目的 探讨非老年成人初发急性髓系白血病(AML)患者年龄相关的临床特征、早期治疗反应和预后。 方法 回顾性分析2008年1月至2017年12月收治的18~65岁初发AML(非急性早幼粒细胞白血病)连续病例,分析不同年龄组患者初诊时疾病特征、早期治疗反应、复发和生存,以及相关影响因素。 结果 共收集1 097例患者,男性591例(53.9%),中位年龄42岁。随着年龄的增长,患者WBC显著下降(P=0.003),PLT显著上升(P=0.034),骨髓原始细胞比例显著下降(P=0.021)。SWOG危险度在各年龄组的分布差异无统计学意义(P=0.063)。NPM1阳性伴FLT3-ITD阴性的患者比例随年龄增长显著上升(P<0.001)。多因素分析显示,在总人群中,年龄增加是获得形态学无白血病状态(MLFS)(P=0.053)、完全缓解(CR)(P=0.004)和总生存(OS)(P=0.070)的不利影响因素,但在接受标准诱导治疗的患者中,年龄增加仅与CR相关(P=0.075),而与MLFS和OS无关。 结论 非老年初发AML患者的临床、细胞遗传学和分子学特征随年龄变化而不同。在接受标准诱导治疗的患者中,年龄增加与获得MLFS和OS均无显著相关性。
Collapse
|
80
|
Lee HB, Kim KE, Ju YW, Jung JG, Ryu HS, Lee SB, Lee JW, Lee HJ, Kim MS, Kwon S, Kim J, Kim C, Moon HG, Noh DY, Ahn SH, Park IA, Kim S, Yoon S, Kim A, Han W. Abstract P2-07-10: Not presented. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-07-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was not presented at the conference.
Citation Format: Lee H-B, Kim KE, Ju YW, Jung J-G, Ryu H-S, Lee SB, Lee JW, Lee HJ, Kim M-S, Kwon S, Kim J, Kim C, Moon H-G, Noh D-Y, Ahn S-H, Park I-A, Kim S, Yoon S, Kim A, Han W. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-10.
Collapse
|
81
|
Ju YW, Jung JG, Kim KE, Kim Y, Lee E, Lee HB, Moon HG, Han W, Noh DY. Abstract P2-14-15: Breast cancer-related lymphedema: Morbidity of sentinel node biopsy. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-14-15] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Purpose:
Sentinel lymph node biopsy (SLNB) lowers morbidity of lymphedema then axillary lymph node dissection (ALND). However, there has been concern about incidence of lymphedema after SLNB especially when the number of harvested nodes during sentinel node biopsy procedure is more than a few. In this study, we assessed lymphedema incidence and its risk factors including the number excised lymph nodes in patients who underwent SLNB.
Methods:
Between January, 2011 and April, 2012, the records of 910 consecutive patients who underwent breast surgery with axillary staging (SLNB/ALND) for breast cancer at Seoul National University Hospital were reviewed. Lymphedema was assessed by circumferential upper extremity measurements. The lymphedema was defined as > 1cm for either the upper arm or the forearm. Patients with clinical records of the treatment for lymphedema in the rehabilitation clinic were regarded as having lymphedema. Univariate and multivariate analyses were performed to identify potential risk factors associated with lymphedema. Association of number of excised lymph nodes with lymphedema was analyzed by Spearman rank correlation coefficient.
Results:
At median follow-up of 69.8 months, 231 patients (25.4%) presented with lymphedema. In univariate analysis, body mass index (BMI) (P<0.001), T stage (P<0.001), N stage (P<0.001), type of surgery (P<0.001), ALND (P<0.001), neoadjuvant chemotherapy (P<0.001) and adjuvant chemotherapy (P=0.027) were significantly associated with lymphedema. In multivariate analysis BMI (P<0.001), ALND (P<0.001), neoadjuvant chemotherapy (P=0.044), and radiation therapy (P=0.046) were significantly associated with lymphedema. In patients treated with SLNB only (n=595), the incidence of lymphedema was 16.3% (n=97). In SLNB only subgroup, BMI was only significant risk factor of lymphedema. There was no correlation between number of excised lymph nodes during sentinel lymph node biopsy procedure with incidence of lymphedema (P=0.138).
Conclusion:
The risk of lymphedema is multifactorial in breast cancer surgery and adjuvant treatments. In SLNB alone patients, higher BMI was only significant factor correlated with lymphedema. Excised number of lymph nodes during sentinel biopsy procedure was not associated with lymphedema.
Citation Format: Ju YW, Jung JG, Kim KE, Kim Y, Lee E, Lee H-B, Moon H-G, Han W, Noh D-Y. Breast cancer-related lymphedema: Morbidity of sentinel node biopsy [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-15.
Collapse
|
82
|
Kim HJ, Noh WC, Nam SJ, Park BW, Lee ES, Im SA, Jung YS, Yoon JH, Kang SS, Park KH, Lee SJ, Jung J, Lee MH, Cho SH, Kim SY, Kim HA, Han SH, Han W, Hur MH, Ahn SH. Abstract P4-14-04: Time course changes in serum FSH, estradiol, and menstruation restoration in premenopausal patients with breast cancer taking adjuvant tamoxifen after completing chemotherapy: A report from the ASTRRA study. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-14-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND
Assessment of restoration of ovarian function after chemotherapy is critical with respect to the initiation of different types of endocrine treatment in young high risk breast cancer patients
METHODS
In total, 1289 women who remained premenopausal or resumed premenopausal status after chemotherapy were randomized to receive 5 years of tamoxifen or 5 years of tamoxifen plus 2 years of ovarian suppression. The patients who did not resume menstruation were followed up for 2 years with tamoxifen treatment after finishing chemotherapy. Prospectively collected consecutive post-chemotherapy hormone and menstruation data were available for 705 breast cancer patients who enrolled tamoxifen-only treatment group or did not resume menstruation during follow up. This analysis evaluated the proportion of patients with pre-menopausal FSH levels (<30 mIU/ml), E2 levels (340 pg/ml), and menstruation at any time point during treatment with tamoxifen.
RESULTS
During 5 years of tamoxifen treatment after chemotherapy for premenopausal breast cancer patients, 62% of patients resumed menstruation. Menstruation returned in 92% of patients under 35 years old but only in 31% of patients over 45 years old. Ovarian function, defined by serum FSH and E2 levels, resumed in 94% and 65% of patients, respectively, over 5 years. Most patients achieved ovarian function restoration during the first 2 years after chemotherapy, with 47.1% resuming menstruation and 86.2% and 50.3% achieving pre-menopausal FSH and E2 levels, respectively, in the first 2 years. Clinical factors related to menstruation restoration were younger age (HR = 6.38, 95% CI 1.33-3.47), 6 month hormone profile after chemotherapy (FSH<30: HR=1.67, 95% CI 1.28-2.17; E2 >40: HR=2.96, 95% CI 2.25-3.89), and anthracycline without taxane chemotherapy (HR=1.63, 95% CI 1.25-2.13).
CONCLUSIONS
During 5 years of tamoxifen treatment after chemotherapy, half of patients experienced menstruation restoration, including most very young patients under 35 years. The majority of patients experienced menstruation restoration in the first 2 years of tamoxifen treatment.
Citation Format: Kim HJ, Noh WC, Nam SJ, Park B-w, Lee ES, Im SA, Jung YS, Yoon JH, Kang SS, Park KH, Lee S-J, Jung J, Lee MH, Cho SH, Kim SY, Kim H-A, Han S-H, Han W, Hur MH, Ahn SH. Time course changes in serum FSH, estradiol, and menstruation restoration in premenopausal patients with breast cancer taking adjuvant tamoxifen after completing chemotherapy: A report from the ASTRRA study [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-14-04.
Collapse
|
83
|
Lee DW, Ryu HS, Lee KH, Jin MS, Woo GU, Suh KJ, Yang Y, Kim HJ, Lee HB, Kim TY, Moon HG, Han W, Park IA, Noh DY, Im SA. Abstract P2-07-09: Immune recurrence score (IRS) using 7 immunoregulatory protein expression can predict recurrence in stage I-III breast cancer patients. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-07-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Immune cells in the tumor microenvironment play an essential role in tumor progression and regression. However, immunologic characteristics and their prognostic role have not been clearly identified in breast cancer patients. This study aimed to evaluate the immunologic characteristics and their prognostic role in breast cancer patients.
Methods: This study enrolled pathologically proven stage I-III breast cancer patients. We performed immunohistochemical staining in stromal tumor-infiltrating lymphocytes (TILs) using 10 immune markers (PD-1, PD-L1, PD-L2, IDO, TIM3, OX40, OX40L, B7-H2, B7-H3, B7-H4) with known/possible clinical relevance. Expression of PD-1, PD-L1, and PD-L2 was also measured in adjacent tumor tissue. Intensity and proportion of the staining was measured for each immune marker. The intensity of immunohistochemical staining (IS, intensity score) was graded as follows: 0 (negative), 1 (weak), 2 (moderate), 3 (strong). The proportion of staining (PS, proportion score) was graded as follows: 0 (stain under <1%), 1 (1% to 5%), 2 (5% to 10%), 3 (10 to 25%), 4 (25% to 50%), Grade 5 (> 50%). Immune markers were defined as positive with one of the following; IS 1 with PS over 3, IS 2 with PS over 2, IS 3 with PS over 1.
Results: A total of 392 patients, 271 (69.1%) luminal A, 36 (9.2%) luminal B, 32 (8.2%) HER2-positive, and 53 (13.5%) triple negative breast cancers were included. In total, PD-1 was expressed by stromal TILs in 130 (33.2%) patients, PD-L1 in 47 (12.0%), PD-L2 in 109 (27.8%), B7-H2 in 225 (57.4%), B7-H3 in 227 (57.9%), B7-H4 in 106 (27.0%), TIM3 in 111 (28.3%), IDO in 96 (24.5%), OX40 in 137 (34.9%), and OX40L in 165 (42.1%). In addition, PD-L1 was expressed in 15 (3.8%) tumor tissue, PD-L2 in 237 (60.5%), and PD-1 was not expressed in tumor tissue. Each breast cancer subtype showed different immunologic characteristics. Expression of PD-1 (stromal TILs) and PD-L1 (Tumor and stromal TILS) was higher in HER2-positive and triple negative breast cancer. By contrast, expression of TIM-3, OX40, and OX40L by stromal TILs were higher in luminal A and luminal B breast cancer. In the univariate analysis, expression of B7-H3 was associated with worse DFS and expression of OX40 and B7-H4 was associated with favorable DFS. Expression of PD-L1, PD-L2, OX40L, and B7-H2 had a tendency of favorable DFS. We devised an immune recurrence score (IRS) using 7 markers with prognostic value (B7-H2, B7-H3, B7-H4, OX40, OX40L, PD-L1, and PD-L2). Patients were classified as high-risk (31 patients, 7.9%), intermediate-risk (265, 67.6%), or low-risk (96, 24.5%) according to 7 immune marker expression. In the multivariate analysis, IRS low-risk (adjusted HR, 0.14; 95% CI, 0.04 – 0.45; p = 0.001) and intermediate-risk (adjusted HR, 0.32; 95% CI, 0.16 - 0.656.42; p = 0.002) had significantly lower risk of recurrence compared with high-risk. In the subgroup analysis, the prognostic role of IRS were maintained in both luminal A patients and non-luminal A patients.
Conclusions: This study identified immunologic characteristics of breast cancer patients using 10 immune markers. In addition, we devised an IRS with 7 immune markers which may predict recurrence in stage I-III breast cancer patients.
Citation Format: Lee D-W, Ryu HS, Lee K-H, Jin M-S, Woo G-U, Suh KJ, Yang Y, Kim H-J, Lee H-B, Kim T-Y, Moon H-G, Han W, Park IA, Noh D-Y, Im S-A. Immune recurrence score (IRS) using 7 immunoregulatory protein expression can predict recurrence in stage I-III breast cancer patients [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-07-09.
Collapse
|
84
|
Moon HG, Choi SH, Park Y, Jung JG, Ju YW, Kim KE, Kim Y, Lee E, Lee HB, Han W, Noh DY, Yoon HJ. Abstract P4-14-09: A nationwide data on the cardiovascular protective effect of tamoxifen and aromatase inhibitor in postmenopausal women with breast cancer. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p4-14-09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
A large proportion of breast cancer patients receive hormonal therapy as their adjuvant treatment options. For postmenopausal women, the initial choice for the hormonal therapy is aromatase inhibitor (AI), and tamoxifen (TM) is reserved for women experiencing severe side effects against AI or having low bone density. An important but unresolved clinical question regarding the use of AI in postmenopausal women is the safety of AI regarding the risk cardiovascular events. Studies have shown inconsistent results over the cardiovascular safety of AI and TM. In this study, we investigated the risk of developing cardiovascular and cerebrovascular events in women with breast cancer who receive hormonal therapy using AI, TM, or both.
To this end, we used the National Health Insurance Sharing Service in Korea which is provided by National Health Insurance Service. The database provides anonymized insurance data for research purposes after the approval of the review committee. In the database, we identified 47,569 women with the age older than 55 who were diagnosed with breast cancer. Patients were classified as no hormonal treatment group (n=18,807), AI group (n=19,584), TM group (n=7,081), or Switch group (n=2,097). The Switch group was defined as the women with history of both AI and TM prescriptions. During the studied period, a total of 2,032 cardiovascular or cerebrovascular events (CVE) were recorded.
Overall, the women prescribed with TM had significantly less hazard ratio for developing CVE when compared to the women who did not receive any hormonal treatment (HR 0.809 95% C.I. 0.706-0.928). However, this protective effect of tamoxifen was not observed in either AI or Switch group (HR 0.917 95% C.I. 0.833-1.010, and HR 0.856 95% C.I. 0.695-1.053, respectively). The protective effect of TM was also similar in women older than 60 (HR 0.808 95% C.I. 0.696-0.938). The cardiovascular and cerebrovascular protective effects of tamoxifen was also substantial in high risk women defined by their family history of cardiovascular diseases and the diagnosis of hypertension or diabetes.
Our results suggest that the use of TM is associated with a substantial protective effect against developing cardiovascular or cerebrovascular events in women with breast cancer. However, the protective effect was not observed for women receiving AI. Our data suggest the potential tailored approach in hormonal treatment in breast cancer patients who are at high risk of cardiovascular of cerebrovascular events.
Citation Format: Moon H-G, Choi SH, Park Y, Jung JG, Ju YW, Kim KE, Kim Y, Lee E, Lee H-B, Han W, Noh D-Y, Yoon H-J. A nationwide data on the cardiovascular protective effect of tamoxifen and aromatase inhibitor in postmenopausal women with breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-14-09.
Collapse
|
85
|
Ruan G, Xu J, Wang K, Zheng S, Wu J, Ren J, Bian F, Chang B, Zhu Z, Han W, Ding C. Associations between serum S100A8/S100A9 and knee symptoms, joint structures and cartilage enzymes in patients with knee osteoarthritis. Osteoarthritis Cartilage 2019; 27:99-105. [PMID: 30240939 DOI: 10.1016/j.joca.2018.08.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 08/12/2018] [Accepted: 08/28/2018] [Indexed: 02/02/2023]
Abstract
OBJECTIVE Animal studies suggest that S100A8/S100A9 may be involved in the pathogenesis of osteoarthritis (OA); however, there has been no clinical study examining the associations between serum S100A8/S100A9 and knee symptoms, joint structures and cartilage degradation enzymes in knee OA patients so far. Therefore, this study was designed to investigate the cross-sectional associations between serum levels of S100A8/S100A9 and the outcomes in patients with knee OA. DESIGN A total of 141 subjects with clinical knee OA were included. Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score was used to assess joint symptoms. Magnetic resonance imaging (MRI) was used to measure knee structural abnormalities including cartilage defects. Knee radiography was used to assess joint space narrowing (JSN), osteophytes and the radiographic severity of OA. Enzyme-linked immunosorbent assay (ELISA) was used to measure the serum levels of S100A8/S100A9, matrix metalloproteinase (MMP)-3, MMP10 and MMP13. RESULTS In multivariable analyses, serum S100A8/S100A9 were positively associated with total WOMAC score (β: 0.111 per 10 ng/ml, P = 0.021), WOMAC weight-bearing pain (β: 0.015 per 10 ng/ml, P = 0.043) and WOMAC physical dysfunction (β: 0.091 per 10 ng/ml, P = 0.010), and had positive associations with total cartilage defects and cartilage defects at lateral femoral, lateral tibial and medial femoral sites (ORs: 1.006-1.008 per 10 ng/ml, all P < 0.05) and serum levels of MMP3 (β: 0.002 per 10 ng/ml, P = 0.032) in patients with clinical knee OA. CONCLUSIONS Serum levels of S100A8/S100A9 were positively associated with increased knee symptoms, cartilage defects and serum cartilage degradation enzymes in patients with knee OA, suggesting that S100A8/S100A9 may have a role to play in knee OA. Future longitudinal studies are required to confirm these findings.
Collapse
|
86
|
Chang J, Zhu Z, Liao Z, Meng T, Zheng S, Cicuttini F, Winzenberg T, Wluka A, Jiang D, Han W, Ding C. A novel method for assessing proximal tibiofibular joint on MR images in patients with knee osteoarthritis. Osteoarthritis Cartilage 2018; 26:1675-1682. [PMID: 30195044 DOI: 10.1016/j.joca.2018.08.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Revised: 07/30/2018] [Accepted: 08/28/2018] [Indexed: 02/02/2023]
Abstract
OBJECTIVES To validate a method to measure the morphological parameters of the proximal tibiofibular joint (PTFJ) in patients with knee osteoarthritis (OA). METHODS 408 participants were examined in this cross-sectional subject-based study. We calculated the fibular contacting area of PTFJ (S) and its projection areas onto the horizontal plane (load-bearing area, Sτ), the sagittal plane (lateral stress-bolstering area, Sφ) and the coronal plane (posterior stress-bolstering area, Sυ). Joint space narrowing (JSN) and osteophyte was measured using radiographs. Cartilage defects, bone marrow lesions (BMLs) and cartilage volume were evaluated using magnetic resonance imaging (MRI). RESULTS The average PTFJ fibular contacting area was 2.4 cm2 (SD, ±0.7 cm2). Intra-observer and inter-observer reliabilities of measures of PTFJ morphological parameters were excellent (≥0.90). S, Sτ and Sφ were significantly associated with JSN in the medial tibiofemoral compartment (PR: 1.40, 95% CI 1.10-1.78; PR: 1.65, 95% CI 1.25-2.18 and PR: 0.53, 95% CI 0.29-0.97, respectively). There was a significantly positive association between S, Sτ and medial and/or femoral tibial cartilage defects. S, Sτ and Sυ were significantly and positively associated with medial and/or femoral tibial BMLs (PR: 1.36, 95% CI 1.12-1.64; PR: 1.47, 95% CI 1.17-1.83; and PR: 1.39, 95% CI 1.06-1.82, respectively) after adjustment. S and Sτ were significantly and negatively associated with medial tibial cartilage volume. CONCLUSIONS This novel method to assess the morphological parameters of PTFJ in MRI is reproducible. These parameters are associated with knee radiographic and MRI-based OA-related structural abnormalities, suggesting clinical construct validity. Its predictive validity needs to be examined in future longitudinal studies.
Collapse
|
87
|
Rizzo VM, Han W, Kang S, Rowe JM, Kukowski R, Golden R. THE IMPACT OF THE AMBULATORY INTEGRATION OF MEDICAL AND SOCIAL (AIMS) MODEL ON DEPRESSION AND HEALTH RISK. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
88
|
Mao X, Han W. SOCIAL SUPPORT AND SUBJECTIVE WELL-BEING AMONG CHINESE OLDER ADULTS. Innov Aging 2018. [DOI: 10.1093/geroni/igy023.2720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
89
|
Fang Y, Shou J, Han W, Li H, Zhou X, Li D, Cheng H, Wang H, Lou F, Cao S, Pan H. Clinical and molecular characteristics of ALK-rearranged Chinese lung cancer patients. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy441.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
90
|
Maudgal S, Han W, Mishra VS. Alexithymia in Breast Cancer Patients and Their Sisters in Seoul. J Glob Oncol 2018. [DOI: 10.1200/jgo.18.29500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Background: The incidence of breast cancer has more than doubled in South Korea since 1999. Breast cancer in the family affects other members such as first degree relatives. Alexithymia is a psychological construct related to an inability to express ones feelings and has been found to be useful in identifying individuals who might benefit from targeted counseling to address distress. Aim: The purpose of this study was to examine the levels of alexithymia in breast cancer patients, their sisters and healthy controls in South Korea with the aim of identifying individuals who will benefit from targeted counseling. Methods: The Korean version of the alexithymia questionnaire was used to compare the groups. The study group consisted of 98 breast cancer in-patients, out-patients, follow-up cases and lymphedema clinic attendees undergoing treatment at the Breast Care Center, Seoul National University Cancer Hospital, 50 sisters and 43 healthy controls. Results: The highest level of alexithymia was reported in patients, followed by their siblings. Healthy controls reported the lowest level of alexithymia. Difficulty in describing feeling scores has shown significant negative correlation with age and marital status among women with breast cancer. Women 51 years and above and married women have lower scores than those below 50 years aged women and those who are single, in a live-in relationship, widowed or divorced. No such significant correlation was observed among siblings and control group. The intensity of cancer was a significant predictor of the alexithymia score. Patients with T4 stage disease reported the highest levels of alexithymia. No significant differences were found among patients with lower staging. Conclusion: Not only breast cancer patients, but also their sisters show significantly more alexithymia than their healthy counterparts. Counselors can use the alexithymia questionnaire to identify persons who require support to prevent or reduce psychological problems in patients and siblings.
Collapse
|
91
|
Byeon EH, Kim J, Han W, Shim MS. ISQUA18-2308Indicator Linkage Management System (ILMS) and Physicians’ Prescription Patterns. Int J Qual Health Care 2018. [DOI: 10.1093/intqhc/mzy167.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
92
|
Han W. Personalized neoadjuvant strategy in luminal A breast cancer to increase BCS rate (PLATO study). Ann Oncol 2018. [DOI: 10.1093/annonc/mdy318.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
93
|
Ruan G, Xu J, Wang K, Wu J, Zhu Q, Ren J, Bian F, Chang B, Bai X, Han W, Ding C. Associations between knee structural measures, circulating inflammatory factors and MMP13 in patients with knee osteoarthritis. Osteoarthritis Cartilage 2018; 26:1063-1069. [PMID: 29753949 DOI: 10.1016/j.joca.2018.05.003] [Citation(s) in RCA: 31] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 02/25/2018] [Accepted: 05/03/2018] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To investigate cross-sectional associations between serum level of Matrix metalloproteinase (MMP)13 and knee structural measures and circulating inflammatory factors in patients with symptomatic knee osteoarthritis (OA). DESIGN A total of 149 subjects with symptomatic knee OA were included. Magnetic resonance imaging was used to measure infrapatellar fat pad (IPFP) volume, IPFP signal intensity alternation, cartilage volume and cartilage defects. Knee radiography was used to assess radiographic OA using the Kellgren-Lawrence (K-L) grading system. Enzyme-linked immunosorbent assay was used to measure the serum levels of inflammatory factors and MMP13. RESULTS In multivariable analyses, serum MMP13 was negatively associated with cartilage volume at patellar site (β: -32.94 mm3 per 10 ng/ml, P < 0.05), and positively associated with cartilage defect at medial femoral site (OR: 1.13 per 10 ng/ml, P < 0.05). Also, MMP13 was positively associated with K-L grading and IPFP signal intensity alteration (OR: 1.14 and 1.15 per 10 ng/ml, respectively, both P < 0.05), and negatively associated with IPFP volume (β: -0.34 cm3 per 10 ng/ml, P < 0.05). Furthermore, serum level of adiponectin was negatively associated serum MMP13 quartiles (OR: 0.66 per 10 μg/ml, P < 0.05), and serum levels of tumor necrosis factor (TNF)-α, interleukin (IL)-8 and IL-18 were positively associated with serum MMP13 quartiles (ORs: 1.01-1.18 per 10 pg/ml, all P < 0.05). CONCLUSIONS Serum level of MMP13 was associated with knee structural abnormalities as well as serum inflammatory factors. These suggest that systemic MMP13 may play a role in knee OA, and could be regulated by inflammatory factors.
Collapse
|
94
|
Moldenhauer S, Wu M, Dütsch M, Scheffel T, Hellweg R, Holloschi A, Abel F, Han W, Moldenhauer A. Acupuncture-induced Mobilization of Stem Cells with Neurogenic Potential in Patients with Spinal Cord Injuries. J Acupunct Meridian Stud 2018. [DOI: 10.1016/j.jams.2018.08.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
95
|
Chang J, Liao Z, Lu M, Meng T, Han W, Ding C. Systemic and local adipose tissue in knee osteoarthritis. Osteoarthritis Cartilage 2018; 26:864-871. [PMID: 29578044 DOI: 10.1016/j.joca.2018.03.004] [Citation(s) in RCA: 54] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2017] [Revised: 02/28/2018] [Accepted: 03/15/2018] [Indexed: 02/08/2023]
Abstract
Knee osteoarthritis (OA) is the most common joint disease. Body adipose tissue has been shown to be related to the development and progression of knee OA. Among systemic adipose tissues, subcutaneous adipose tissue is significantly and negatively associated with muscle mass and forces, and could be related to the presence and progression of knee OA. Visceral adipose tissue is associated with increased cartilage loss and production of pro-inflammatory cytokines. Intra-muscular adipose tissue is associated with knee osteoarthritic changes, but it remains controversial if inter-muscular adipose tissue has a role to play in the pathogenesis for knee OA. Knee local adipose tissue such as infrapatellar fat pad (IPFP) can interact with neighbouring tissues, and may have a biphasic effect in knee OA. The underlying mechanisms for the roles of the systemic and local fat in knee OA could be related to biomechanical, metabolic, inflammatory factors and fat fibrosis, which may have a separated or combined effect on OA. Tissue engineering from systemic or local adipose tissue is a new research direction, and adipose tissue-derived stem cells from systemic or local adipose tissue may be beneficial for OA cartilage repair. Research on systemic and local adipose tissue would provide novel approaches for prevention and treatment of knee OA, but further studies are required to explore the roles of different adipose tissues in knee OA and the effects of stem cells derived from different adipose tissues on knee OA.
Collapse
|
96
|
Ha C, Park Y, Kim J, Rhim J, Kim M, Han W, Lee K, Lee L, Park H, Park H. Allogeneic stem cells versus microfracture for cartilage repair in osteoarthritis. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
97
|
Kim J, Ha C, Rhim J, Park Y, Kim M, Han W, Lee K, Lee L, Park H, Park H. Different characteristics of msc isolated from differentiated layers of chorionic membrane&trophoblastic layers of term placenta. Cytotherapy 2018. [DOI: 10.1016/j.jcyt.2018.02.109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
98
|
Xiang J, Moyana T, Chen Z, Han W, Ping T, Li E. Production and Characterization of a Tumor-Specific Monoclonal Antibody Act19 Recognizing an Epitope Distinctive from Sialosyl-Tn on the TAG72 Antigen. TUMORI JOURNAL 2018; 79:58-65. [PMID: 7684540 DOI: 10.1177/030089169307900113] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims A murine monoclonal antibody ACT19 directed at the TAG72 tumor-associated antigen, which was originally defined by the B72.3 antibody, was established. Methods This was done by immunizing mice with the bovine mucin followed by the selection of hybridomas secreting antibodies with the desired specificity. In order to better characterize this antibody, its immunoreactivity was compared to that of the B72.3 antibody. Results The data showed that the ACT19 antibody bound specifically to the TAG72 antigen as the B72.3 antibody did. However, there were some differences between ACT19 and B72.3. Firstly, the immunoreactivity of ACT19 for the bovine mucin was lower than that of B72.3. Secondly, the immunoreactivity of ACT19 for the TAG72 antigen was not inhibited by N-acetylgalactosamine, nor was that of B72.3. Thirdly, ACT19 did not compete the binding reactivity of B72.3 for the TAG72 antigen. This suggests that the epitope defined by ACT19 is different from the sialosyl-Tn epitope recognized by B72.3. Immunoperoxidase staining of various tumors, normal and embryonic tissues for ACT19 was carried out. For the various tumors, only adenocarcinomas from the colon and stomach showed remarkable positivity. All the normal tissues were negative, except for weak positivity involving the zona reticularis of the adrenal cortex, and intestinal goblet cells. Embryonic tissues showed a wide spectrum of positivity with staining of the small and large intestine, stomach and renal tubules. Conclusions The ACT19 antibody appears to be a useful marker for colon and stomach cancers, and this additional anti-TAG72 antibody may be useful in conjunction with the B72.3 antibody in pathology and clinical application.
Collapse
|
99
|
Liu Y, Chen X, Han W, Zhang Y. Tisagenlecleucel, an approved anti-CD19 chimeric antigen receptor T-cell therapy for the treatment of leukemia. Drugs Today (Barc) 2018; 53:597-608. [PMID: 29451276 DOI: 10.1358/dot.2017.53.11.2725754] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
On August 30, 2017, the U.S. Food and Drug Administration (FDA) approved Novartis' tisagenlecleucel (CTL-019, Kymriah), which is a synthetic bioimmune product of anti-CD19 chimeric antigen receptor (CAR) T cells, for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). This was a milestone in tumor immunology on account of the significant antitumor effect of tisagenlecleucel for the treatment of relapsed/refractory B-ALL patients. Conventional standard therapies for B-ALL have high failure rates, thus developing new therapies is crucial for patients with B-ALL. Results from clinical trials indicate that anti-CD19 CAR T-cell therapies could successfully induce high response rates in B-ALL patients. However, related toxicities, such as cytokine release syndrome and CAR T-cell-related encephalopathy syndrome, may be severe or even fatal, and the management of such toxicities is therefore vital. This review will focus on the clinical application of anti-CD19 CAR T-cell therapy in B-ALL treatment, including design features of CAR constructs, therapeutic use of tisagenlecleucel, CAR T-cell therapy clinical trials and related toxicity, and prospects for cancer immunotherapy.
Collapse
|
100
|
Kim K, Han W, Lee H, Lee E, Kim Y, Park J, Ju Y, Moon H, Noh D. Is necessary neoadjuvant chemotherapy in metaplastic breast cancer? Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30521-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|